{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:09:54Z","timestamp":1777871394190,"version":"3.51.4"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01AI166126"],"award-info":[{"award-number":["K01AI166126"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["P30AI060354"],"award-info":[{"award-number":["P30AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.1093\/cid\/ciag002","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T12:25:13Z","timestamp":1767443113000},"page":"e743-e745","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3761-6154","authenticated-orcid":false,"given":"Amir M","family":"Mohareb","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Center for Global Health, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Boyd","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Amsterdam Institute for Infection & Immunity (AII), Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026043013151490200_ciag002-B1","author":"National Institutes of Health, HIV Medicine Association, and Infectious Diseases Society of America"},{"key":"2026043013151490200_ciag002-B2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/jvh.13461","article-title":"Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy","volume":"28","author":"Mohareb","year":"2021","journal-title":"J Viral Hepat"},{"key":"2026043013151490200_ciag002-B3","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"The Lancet"},{"key":"2026043013151490200_ciag002-B4","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.jve.2024.100574","article-title":"Virological and serological outcomes in people with HIV-HBV coinfection who had discontinued tenofovir-containing antiretroviral therapy: results from a prospective cohort study","volume":"10","author":"Mohareb","year":"2024","journal-title":"J Virus Erad"},{"key":"2026043013151490200_ciag002-B5","doi-asserted-by":"publisher","author":"Denyer RV, Tate JP, Benator DA, et al.","year":"2026","DOI":"10.1093\/cid\/ciag001"},{"key":"2026043013151490200_ciag002-B6","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004353","article-title":"Tenofovir interruption among people with HIV and HBV: HBV monitoring and risk of HBV reactivation and hepatitis flare","author":"Dieterich","year":"2025","journal-title":"AIDS"},{"key":"2026043013151490200_ciag002-B7","doi-asserted-by":"crossref","first-page":"107294","DOI":"10.1016\/j.ijid.2024.107294","article-title":"Kinetics of hepatitis B virus replication in anti-HBc positive\/HBsAg-negative people with HIV switching to tenofovir sparing therapy","volume":"150","author":"Salpini","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026043013151490200_ciag002-B8","doi-asserted-by":"crossref","first-page":"ofy251","DOI":"10.1093\/ofid\/ofy251","article-title":"Hepatitis B virus (HBV) infection and re-activation during nucleos(t)ide reverse transcriptase inhibitor\u2013sparing antiretroviral therapy in a high\u2013HBV endemicity setting","volume":"5","author":"Abdullahi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026043013151490200_ciag002-B9","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.lanmic.2025.101076","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field","volume":"6","author":"Lumley","year":"2025","journal-title":"Lancet Microbe"},{"key":"2026043013151490200_ciag002-B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf634","article-title":"Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: a case series and lessons for practice","author":"Olcott","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026043013151490200_ciag002-B11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000000927","article-title":"Lamivudine monotherapy-based cART is efficacious for HBV treatment in HIV\/HBV coinfection when baseline HBV DNA<20,000 IU\/ml","volume":"72","author":"Li","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag002\/67089743\/ciag002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e743\/67089743\/ciag002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e743\/67089743\/ciag002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:15:17Z","timestamp":1777569317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e743\/8495844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,24]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag002","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2026,2,24]]}}}